Cancers (Dec 2022)

The Dual Role of PDCD10 in Cancers: A Promising Therapeutic Target

  • Jingdian Liu,
  • Kai Zhao,
  • Sisi Wu,
  • Chaoxi Li,
  • Chao You,
  • Junwen Wang,
  • Kai Shu,
  • Ting Lei

DOI
https://doi.org/10.3390/cancers14235986
Journal volume & issue
Vol. 14, no. 23
p. 5986

Abstract

Read online

Programmed cell death 10 (PDCD10) was initially considered as a protein associated with apoptosis. However, recent studies showed that PDCD10 is actually an adaptor protein. By interacting with multiple molecules, PDCD10 participates in various physiological processes, such as cell survival, migration, cell differentiation, vesicle trafficking, cellular senescence, neurovascular development, and gonadogenesis. Moreover, over the past few decades, accumulating evidence has demonstrated that the aberrant expression or mutation of PDCD10 is extremely common in various pathological processes, especially in cancers. The dysfunction of PDCD10 has been strongly implicated in oncogenesis and tumor progression. However, the updated data seem to indicate that PDCD10 has a dual role (either pro- or anti-tumor effects) in various cancer types, depending on cell/tissue specificity with different cellular interactors. In this review, we aimed to summarize the knowledge of the dual role of PDCD10 in cancers with a special focus on its cellular function and potential molecular mechanism. With these efforts, we hoped to provide new insight into the future development and application of PDCD10 as a clinical therapeutic target in cancers.

Keywords